Dalmeet Singh Chawla is a freelance science journalist based in London. His work has been featured in Nature, Science, Slate, Undark, The Economist, New Scientist and Pacific Standard, among other publications. See more about his work here: www.dalmeets.com.
Dalmeet Singh Chawla
Contributing writer
From this contributor
Neuroscience conference policy draws confusion, apology
NeurIPS organizers apologized and altered course after issuing a policy that barred submissions from researchers at U.S.-government-sanctioned institutions.
Neuroscience conference policy draws confusion, apology
By
Dalmeet Singh Chawla
27 March 2026 | 5 min read
Faked results lead to retraction of high-profile cancer neuroscience study
An investigation found that the experiments required more animals than the scientists had purchased.
Faked results lead to retraction of high-profile cancer neuroscience study
By
Dalmeet Singh Chawla
18 June 2024 | 4 min read
‘Tainted kids,’ other odd phrases cropping up in autism studies
The “tortured phrases” — strangely worded paraphrases of established terms — may be the work of software that attempts to disguise plagiarism.
‘Tainted kids,’ other odd phrases cropping up in autism studies
By
Dalmeet Singh Chawla
2 May 2022 | 4 min read
Why was a study about autism cited by a paper on plant beauty?
Autism studies are appearing in the reference lists of entirely unrelated papers, suggesting what a few scholars worry is a plot to manipulate citations.
Why was a study about autism cited by a paper on plant beauty?
By
Dalmeet Singh Chawla
21 January 2022 | 5 min read
Large study supports discarding the term ‘high-functioning autism’
Autistic people described as ‘high functioning’ because they do not have intellectual disability often still struggle with daily living skills.
Large study supports discarding the term ‘high-functioning autism’
By
Dalmeet Singh Chawla
3 July 2019 | 3 min read
Explore more from The Transmitter
Supported by a $40 million NIH grant, Yale brain shuttle technology raises questions
Yale University claims its STEP platform might be able to deliver gene-editing tools into the brain via multiple routes. Researchers are eager to see more.
Supported by a $40 million NIH grant, Yale brain shuttle technology raises questions
Yale University claims its STEP platform might be able to deliver gene-editing tools into the brain via multiple routes. Researchers are eager to see more.
By
Natalia Mesa
3 June 2026 | 11 min read
What counts as a ‘naturalistic’ behavior?
Nedah Nemati explains how neuroscience methods and the lived experience of the scientists themselves shape how we define the behaviors we seek to explain.
What counts as a ‘naturalistic’ behavior?
Nedah Nemati explains how neuroscience methods and the lived experience of the scientists themselves shape how we define the behaviors we seek to explain.
By
Paul Middlebrooks
3 June 2026 | 1 min read
Allen Institute sets sights on treatments for five brain diseases
The Brain Health Accelerator program aims to harness single-cell transcriptomics and cell-type-specific genetic tools to develop treatments for Alzheimer’s, Huntington’s and Parkinson’s diseases, Lewy body dementia and ALS.
Allen Institute sets sights on treatments for five brain diseases
The Brain Health Accelerator program aims to harness single-cell transcriptomics and cell-type-specific genetic tools to develop treatments for Alzheimer’s, Huntington’s and Parkinson’s diseases, Lewy body dementia and ALS.
By
Calli McMurray
2 June 2026 | 5 min read